Effects of salbutamol on rat diaphragm contractility by Heijden, H.F.M. van der et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Effects of salbutamol on rat diaphragm contractility
H. F. M. VAN DER HEIJDEN, R. H. H. VAN BALKOM, H. T. M. FOLGERING, 
C. L. A. VAN HERWAARDEN, AND P. N. R. DEKHUIJZEN
Department of Pulmonary Diseases, University Hospital Nijmegen,
6500 HB Nijmegen, The Netherlands
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H. T. M. Folgering, C. L. A* Van Herwaarden, and P. N. R. 
Dekhuijzen. Effects of salbutamol on rat diaphragm contrac­
tility. J. AppL Physiol. 81(3): 1103-1110, 1996.—The aim of 
this study was to investigate 1 ) the effects and time course of 
single doses of salbutamol on isometric contractile properties 
of isolated rat diaphragm strips and 2) whether these effects 
were caused by a direct effect on the muscle* Two experiments 
were performed. In one, salbutamol was administered subcu- 
taneously in doses of 12.5, 25, 50, or 100 pg/kg (25 and 
50 pg/kg sc resulted in serum concentrations of —9 and 
—15 pg/1, respectively, 0.5 h after injection) and in vitro 
contractile properties were determined 0.5, 1, 2, or 4 h after 
administration; in the other, salbutamol was added to the 
tissue bath in a concentration of ^ 2, —10, —20, and —80 pg/1. 
Twitch force, maximal tetanic force, and twitch force-to- 
tetanic force ratio all increased in a dose-dependent way in 
both experiments. The increases in force generation were 
slightly higher after subcutaneous administration. Force- 
frequency curves were shifted upward in both experiments. 
No significant effects of time of salbutamol administration 
were found, but the increase in force generation was most 
pronounced within 2 h after subcutaneous administration. In 
conclusion, in vitro force generation can be improved by low 
concentrations of salbutamol. The slightly higher increases in 
force generation after subcutaneous administration suggest 
that in vivo salbutamol may have additional positive inotro­
pic actions on diaphragm contractility besides a direct p2- 
adrenergic effect on the muscle itself.
contractile properties; dose response; (3-adrenergic agonists; 
respiratory muscles
SEVEKAL s t u d i e s  have indicated that the (^-adrenocep­
tor agonist salbutamol may improve skeletal and respi­
ratory muscle function. In vitro experiments showed 
that salbutamol hyperpolarized membrane potential in 
both peripheral skeletal muscles and diaphragm (6, 
36). Salbutamol increased subtetanic force generation 
in fast-contracting skeletal muscles and decreased force 
in slow-contracting muscles (1). This is consistent with 
the in vivo effects of catecholamines on skeletal muscles 
(4). Experiments in dogs showed no significant increase 
in transdiaphragmatic pressure (Pdi) or twitch force 
(Pt) in fatigued diaphragm after short-term intrave­
nous salbutamol administration (11, 29). In contrast, 
salbutamol did increase diaphragm Pt during compen­
sated metabolic acidosis (12) and increased shortening 
of the canine diaphragm (16). Contradicting effects of 
salbutamol on respiratory muscle function have also 
been described in humans. Two studies showed no 
improvement of Pdi (14) or maximal inspiratory mouth 
pressure (Pimax) (35) in normal subjects. In contrast, 
long-term salbutamol administration in healthy volun­
teers increased Pimax by 7 and 15% after 14 and 21 days 
of oral treatment, respectively (23).
Although several of these studies indicate that salbu­
tamol may increase diaphragm force generation under 
specific circumstances, the exact effects of salbutamol 
on diaphragm contractile properties and its mechanism 
of action have not been fully clarified yet. To our 
knowledge, the in vitro effects of salbutamol on dia­
phragm contractile properties have not been studied. 
The aims of the present study were therefore to 1 ) 
investigate the dose-response effects and time course of 
effects of salbutamol on in vitro isometric contractile 
properties of rat diaphragm and 2) investigate whether 
these effects can be explained by a direct effect on the 
diaphragm. We aimed to study the effects of salbutamol 




Protocol A. Saline or salbutamol (Glaxo-Wellcome, The 
Netherlands) in a dose of 12.5, 25, 50, or 100 pg/kg was 
administered subcutaneously. Salbutamol was dissolved in 
0,9% NaCl, and all rats received a volume of 0.5 ml/kg body 
wt. At 0.5,1, 2, or 4 h after injection, the animals were killed 
and contractile properties of isolated diaphragm strips were 
determined,
Protocol B. Saline or salbutamol in a concentration of
0.01 pM ('-'-3 pg/1), 0.03 pM (—10 pg/1), 0.06 pM (-20 p 
0.3 pM (—80 pg/1) was dissolved in Krebs-Ringer solution 
before each experiment. Subsequently, diaphragm strips were 
mounted in the tissue baths containing this Krebs solution to 
determine direct effects of salbutamol on contractile proper­
ties.
Animals and Ti'eatment
A total number of 125 adult male outbred Wistar rats, aged 
17-20 wk and weight 556 ± 6 (SE) g, were used in these 
experiments. In both protocols, five animals were studied in 
each group. The rats were housed under standard conditions 
and were fed ad libitum. The study was approved by the Animal 
Experiments Committee of the University of Nijmegen.
The salbutamol concentration of 10 pg/1 was based on the 
mean human serum concentration reached after a single oral 
dose of 4 mg, which was -1 0 —20 pg/1 (10). The actual serum 
salbutamol concentrations reached in protocols A  and B were 
measured in all subcutaneously treated rats and in five 
samples obtained from each in vitro concentration. Serum 
samples were obtained from all rats in the study. Blood 
samples were collected from the thoracic cavity immediately 
after excision of the diaphragm and dissection of the aorta 
and vena cava. The samples were subsequently centrifuged 
and stored at — 80°C until analysis. The analysis was per­
formed by using high-performance liquid chromatography 
with fluorescence detection (Scotlab Analytical, Coatbridge, 
Scotland, UK) (3).
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A pilot study showed no effects of any of the salbutamol 
concentrations used on the pH of the oxygenated Krebs 
solution. A maximal increase of Pt was reached within 10 min 
after addition of salbutamol and lasted for ^15 min. There­
fore, a period of 15 min for thermo equilibration and diffusion 
of salbutamol {protocol B )  was applied in both protocols.
The experiments with different doses and time groups were 
performed at random. The investigator (H. F. M. Van Der 
Heijden) was blinded with regard to dose and time of adminis­
tration.
Contractile Properties
The rats were anesthetized with pentobarbital sodium (70 
mg/kg ip). A tracheotomy was performed, and a polyethylene 
canula was inserted. The animals were mechanically venti­
lated with a gas mixture of 95% 0 2-5% CO2 (flow of 0.5 ml‘g 
body wt”1 ■ min"1; respiration frequency of 70 breaths/min).
The diaphragm was quickly cut from the ribs after com­
bined laparotomy and thoracotomy and was immediately 
submersed in cooled oxygenated Krebs solution at a pH of 7.4. 
This Krebs solution consisted of (in mM) 137 NaCl, 4 KC1, 2.7 
CaCl2 , 2 MgCl2 , 1 KH2PO4 , 24 NaHCC>3 , and 7 glucose and 25 
]uM D-tubocurarine (Sigma Chemical, The Netherlands). From 
the middle lateral costal region of each hemidiaphragm, a 
rectangular bundle was dissected parallel to the long axis of 
the muscle fibers. Silk sutures were tied firmly to both ends of 
the bundle. The bundles were suspended in two tissue baths 
containing Krebs solution, maintained at 37°C, and perfused 
with a 95% 02-5% CO2 mixture. One end was connected to an 
isometric force transducer (model 31/1437-10, Sensotec, Co­
lumbus, OH) mounted on a micrometer. Two platinum stimu­
lating electrodes were placed parallel to the bundles. The 
bundles were placed at their optimal length (L0), defined as 
the length at which peak Pt was obtained, Stimuli were 
applied with a pulse duration of 0.2 ms and a train duration of 
250 ms and were delivered by a stimulator (ID-electronics, 
University of Nijmegen, The Netherlands) activated by a 
personal computer. To ensure supramaximal stimulation, the 
bundles were stimulated at '—20% above the voltage at which 
maximal forces were obtained (~6 V over stimulating elec­
trodes). Data acquisition and storage of the amplified signal 
were performed by using a Dash-16 interface on a personal 
computer (Twist-trigger software, ID-electronics, University 
of Nijmegen).
In protocol A, the diaphragm strip dimensions at L 0 were 
18.02 ± 0.18 X 1.59 ± 0.03 X 0.42 ± 0.01 (SE) mm (length X 
width X thickness) and the weight was 24,2 ± 0.6 mg. In 
protocol B , these dimensions were 16.67 ± 0,38 X 1.90 ±
0.07 X 0.59 ± 0.01 mm and their mean weight was 28.2 ±
1.0 mg. After a thermo equilibration period of 15 min, the 
following measurements were performed.
Twitch characteristics. Two twitches were recorded at L 0 to 
determine maximal Pt) contraction time (CT) (time to peak 
Pt), and ha If-relaxation time (RTy2). Average values were 
used for further analysis (7).
M axim al tetanic force (P0). The bundles were stimulated 
twice at 160 Hz to obtain a maximal plateau in force 
generation. The maximal force was defined as the PQ.
Force-frequency characteristics. The bundles were stimu­
lated at 2-min intervals at frequencies of 25, 50, 80,120, and 
160 Hz.
After these measurements* length* thickness, and width of 
each muscle bundle were measured at L0. The bundles were 
weighed, and the cross-sectional area was calculated by 
dividing diaphragm strip weight (in grams) by strip length (in 
centimeters) times specific density (1.056). Pt and P0 were
expressed per cross-sectional area (in kilograms per square 
centimeter), and Pt/P0 was calculated for each muscle bundle.
Statistics
The data obtained from the two diaphragm strips of each 
rat were averaged and used for further analysis. In protocol 
A, two-way analysis of variance (ANOVA) was performed 
using dose and time of administration as separate factors to 
examine salbutamol treatment and time of dosing effects and 
possible interaction between these factors. Interaction be­
tween these factors was not significant for any parameter. 
Therefore, no linear contrast analysis was performed and 
main effects of each factor were considered not to be con­
founded by interaction. The significance of each main effect is 
reported.
In protocol B ,  on e-way ANOVA was performed to determine 
differences between separate concentrations using Duncan’s 
multiple-range test. To evaluate force-frequency characteris­
tics, a two-way ANOVA was performed using dose and 
stimulation frequency as separate factors to assess interac­
tion between these factors. Pearson’s correlation coefficients 
between salbutamol concentration and Pt, P0, and force 
generation at 25-Hz stimulation frequency were computed, 
Finally, the salbutamol effects in protocols A  and B  were 
compared using ¿-tests for separate ranges of salbutamol 
concentrations.
The limit of statistical significance was set at P < 0.05. All 
analyses were performed with the SPSS/PC + package (v5.01) 
(28). All values are means ± SE.
RESULTS
Salbutamol Concentrations
The mean serum salbutamol concentrations reached 
in protocol A are presented in Fig. 1. At 0.5 h after 
injection, salbutamol concentrations could be mea­
sured in all treated rats. Doubling the administered 
dose approximately doubled the serum concentration. 
At later time points, the concentrations were either 
below the lower limit of detection (2 }ig/l) or blank. Only 
at a dose of 100 ug/kg could salbutamol be detected 2 h 
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Fig. 1. Salbutamol concentration curves (protocol A). Values are 
means ± SE. Time is in hours. O, Dose of 12.5 pg/kg sc; • ,  25 P-gA^ g sc; 
□, 50 pg/kg sc; ■, 100 pg/kg sc.
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Table 1. Protocol A  (subcutaneous administration of salbutanol): Pt
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Time After Subcutaneous Administration
Treatment 0.5 h lh 2 h 4 h
Saline 0.441 ±0.037 0.420 ±0.042 0.477 ±0.041 0.431 ±0.072
Salbutamol, pg/kg
12.5 0.553 ±0.050 0.597 ±0.066 0.515 ±0.027 0.520 ±0.025
25 0.588 ±0.038 0.635 ±0.044 0.541 ±0.040 0.526 ±0.041
50 0.609 ±0.057 0.681 ±0.082 0.631 ±0.083 0.558 ±0.038
100 0.735 ±0.025 0.684 ±0.074 0.688 ±0.035 0.594 ±0.067
Values are means ± SE expressed as twitch force (Pt) in kilograms per square centimeter. Significant difference between treatments is found 
at P < 0.001 using 2-way analysis of variance (ANOVA). There are no significant differences between times of salbutamol administration.
In protocol B, the in vitro salbutamol concentrations 
were below the lower limit of detection in four out of five 
samples at 0.01 pM. In the other groups, salbutamol 
concentrations of 10.1 ± 0.8, 22.2 ± 1.6, and 78.3 ±
4.0 jig/1 were measured.
Contractile Properties
Protocol A. TWITCH characteristics and  P0. Salbuta­
mol increased Pt in a dose-dependent fashion (P <
0.001). No significant effects of time of administration 
were found, and no interaction between these factors 
was found. The effects of salbutamol treatment were 
most pronounced at 0.5 and 1 h after administration 
(Table 1). For CT, significant effects were found for dose 
(P < 0.01) and time of administration (P < 0.001). The 
values ranged from 27.6 ± 0.5 to 31,7 ± 0.8 ms. CT was 
increased at 2 h after administration in all salbutamol 
groups except the 50 pg/kg group. RT1/2 ranged from
22.0 ± 0.9 to 26.7 ± 1.4 ms and was not changed by 
salbutamol.
A significant effect of dose on P0 was found (P < 0.01). 
P0 increased in a dose-dependent way in all groups 
(Table 2). No effect of time of administration or interac­
tion between these factors was observed. For Pt/Pos 
significant effects of dose and time of administration 
(both P < 0.001) were found without interaction. Pt/P0 
values ranged from 0.233 ± 0.009 to 0.310 ± 0.006. 
Greatest increases in Pt/P0 were observed 0.5 and 1 h 
after administration of salbutamol. At 4 h after admin­
istration, no effects of salbutamol treatment were found, 
which is in agreement with the absence of salbutamol 
in serum (Fig. 1).
force-frequency characteristics. Significant dose
effects were found for force generation at stimulation 
frequencies of 25 (P < 0,001), 50 (P <  0.01), and 80 Hz 
(P < 0.05). No significant effects of time of administra­
tion or interaction were found. Further two-way ANOVÀ 
of force-frequency characteristics, with salbutamol dose 
and stimulation frequency as factors, showed signifi­
cant effects of salbutamol treatment (P < 0.01 at 0.5, 2, 
and 4 h and P < 0.05 at 1 h after administration). No 
interaction was present between stimulation frequency 
and dose, suggesting that force generation was influ­
enced by salbutamol in a similar way at all stimulation 
frequencies studied. The force-frequency curves ob­
tained 0.5 h after subcutaneous administration are 
shown in Fig. 2,
Protocol B. twitch characteristics and  P0. Pt in­
creased in the presence of salbutamol in a concentration- 
dependent fashion (Table 3). This effect was significant 
at a concentration of ~10 jig/1 and higher. CT was 
increased at all concentrations; RT1/2 did not change at 
any concentration studied. The values ranged from
23.8 ± 1.1 to 25.8 ± 0.7 ms. P0 was increased by 
salbutamol in concentrations of ~10 pg/1 or higher; 
Pt/Po was not changed.
force-frequency characteristics. Force generation 
was increased at all stimulation frequencies (Fig. 3). 
This effect was concentration dependent. In a salbuta­
mol concentration of —80 pg/1, significant increases in 
force production were observed at all stimulation fre­
quencies used. At 25'Hz stimulation, force generation 
was also significantly increased at —10 pg/1 salbutamol. 
Two-way ANOVA of force-frequency characteristics with
Table 2. Protocol A  (subcutaneous administration of salbutamol): P0
Time After Subcutaneous Administration
Treatment 0.5 h lh 2 h 4  h
Saline 1.885 ±0.130 1.815 ±0.213 1.898 ±0.147 1.810 ±0.187
Salbutamol, pg/kg
12.5 2.056 ±0.155 2.166± 0.231 2.051 ±0.092 2.198 ±0.171
25 2.004±0.197 2.314± 0.093 2.039 ±0.115 2.158 ±0.178
50 2.114±0.236 2.292 ±0.264 2.448 ±0.252 2.393 ±0.202
100 2.375 ±0.112 2.320 ±0.205 2.448 ±0.153 2.355 ±0.223
Values are means ± SE expressed as maximal tetanic force (P0) in kilograms per square centimeter. Significant difference between 
treatments is found at P < 0.01 using 2-way ANOVA. There are no significant differences between times of salbutamol administration.
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Fig. 2. Force-frequency characteristics 0.5 h after subcutaneous 
administration of salbutamol. Values are means ± SE. O, Saline- 
treated animals; • ,  12.5 pg/kg; □, 25 pg/kg; ■, 50 pg/kg; A, 100 pg/kg. 
Significant difference between treatments is found at P <  0.01 using 
dose and stimulation frequency as factors in 2-way analysis of 
variance (ANOVA). * Significant difference in treatments for Pt and at 
stimulation frequencies of 25 (P < 0.001), 50 (P < 0.01), and 80 (P <
0.05) Hz using time and dose as factors in 2-way ANOVA. No 
significant effects of time of administration were found.
salbutamol concentration and stimulation frequency as 
factors showed significant effects of salbutamol concen­
tration (P < 0.001). No interaction was found between 
stimulation frequency and concentration, suggesting 
that force generation was influenced by salbutamol in a 
similar way at all stimulation frequencies studied.
Comparison between protocols A and B. Pearson’s 
correlation coefficients between salbutamol concentra­
tion and contractile properties (Pt3 P03 and force genera­
tion at 25 Hz) are summarized in Table 4. Significant 
correlations for all these parameters were found in 
protocol B  and at 0.5 h after injection in protocol A. In 
the overall analysis in protocol A, only Pt showed a 
significant correlation with salbutamol concentration. 
At 1 and 2 h after injection, the correlation coefficients 
were reduced because the number of samples in which 
salbutamol could be detected was reduced.
In Figs. 4 and 5, the effects of specific ranges of 
salbutamol are compared between protocols A  and 5. 
These ranges were set at the lower limit of detection 
(2 pg/1) and the upper limit of the therapeutical concen­
tration after oral administration (20 pg/L). In the saline- 
treated animals, no significant differences in Pt and P0 
between both protocols were observed. In the bundles 
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Fig. 3. Force-frequency characteristics: strictly in vitro effects of 
salbutamol (protocol B ). Values are means ± SE. O, Saline control 
animals; • ,  ^2 pg/1; □, ~10 pg/1; ■, ~20 pg/1; A, -80 pg/1. 
Significantly different (P < 0.05) using 1-way ANOVA compared with:
* saline; v ^2 pg/1 salbutamol.
and P0 were significantly higher in the in vivo experi­
ment {protocol A). Increases in force generation were 
similar at salbutamol concentrations of 2-20 pg/1, but 
at concentrations >20 pg/1 group Pt and P0 were again 
significantly higher in the in vivo experiment (protocol
A \
DISCUSSION
The present study shows that salbutamol improves 
in vitro force generation in rat diaphragm bundles. 
Increases in force generation were most prominent 
within 2 h after subcutaneous administration and were 
dose dependent. Increases in Pt and Pt/P0 were found at 
clinically relevant salbutamol concentrations. Compa­
rable results were found both after subcutaneous injec­
tion and in a strictly in vitro experiment, although 
increases in force generation were highest after subcu­
taneous administration at salbutamol concentrations 
<2 pg/1 and >20 pgA.
Based on body weight and systemic availability, a 
dose of —25 pg/kg sc used in protocol A  is comparable to 
a single oral dose of 4 mg for a person weighing 70 kg 
(57 pg/kg), since absolute systemic availability in hu­
mans is —50% after oral administration due to first 
pass elimination in the intestinal wall (24). This dose 
resulted in a plasma concentration of —10-20 pg/1 in
Table 3. Protocol B : strictly in vitro effects of salbutamol on contractile properties
Treatment Pt) kg/cm2 CT, ms Pu, kg/cm “ Pt/P*
Saline 0.424 ±0.027 25.6 ± 1.1 1.568 ±0.047 0.270 ±0.011
Salbutamol, pg/1 
<2 0.400 ±0.028 28.8 ±1.0* 1.491 ±0.110 0.271 ±0.009
10 0.538 ±0.032*+ 28.6 ± 0.8* 1.897 ±0.102*1 0.285 ±0.011
20 0.534±0.059*+ 29.3 ±0.5* 1.966 ±0.172*t 0.271 ±0.012
80 0.611 ±0.026*+ 28.9 ±1.2* 2.096 ±0.098*t 0.293 ±0.009
Values are means ± SE. CT, contraction time. Significantly different (P<0.05) using 1-way ANOVA compared with: * saline; t ^ 2  pg/l 
salbutamol.
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Table 4. Pearsons correlation coefficients
between salbutamol concentrations
and contractile properties in protocols A  and B
11
Pt Po FF 25 Hz
r P Po P r P
Protocol B (in vitro) 25 0.60 <0.01 0.56 <0.01 0.59 <0.01
Protocol A  (in vivo) 100 0.41 <0.001 0.14 NS 0.22 NS
0.5 h 25 0.68 <0.001 0.40 0.05 0.54 <0.01
lh 25 0.36 NS 0.22 NS 0.21 NS
2h 25 0.38 NS 0.17 NS 0.42 <0.05
n ~ no. of rats. FF, force frequency; NS, not significant.
humans (10), a range usually regarded as the therapeu­
tic range for bronchodilation (18). In the present experi­
ment, a dose of 25 pgAtg sc (serum concentration 
9.3 p.g/1) and the concentration of —10 pgA used in 
protocol B were within this therapeutic range.
Significant effects of time of administration were 
only found for CT and Pt/P0- This increase in CT was 
manifest at 2 h after injection. Pt/P0 increase was most 
pronounced 0.5 and 1 h after injection. At 4 h after 
injection no increase was noted, which was in agree­
ment with the absence of salbutamol in serum. For 
other parameters, no significant time effects were 
found. The effects on Pt generation found in this study 
had a rapid onset of action and were most pronounced 
up to 2 h after subcutaneous administration. There are 
only limited data available on salbutamol pharmacoki­
netics in rats. After oral administration, salbutamol is 
rapidly absorbed and maximal plasma concentration is 
reached within 1-2 h in rats (21). Maximal peripheral 
skeletal muscle concentration was reached at —1—2 h 
after oral administration in rats (21), In the present 
study, the elimination half-life after subcutaneous ad­
ministration appears to be ~0.5 h, The duration of 
effects in our study is ~2 h, which is in agreement with 
the salbutamol concentrations measured. This could 













saline < 2 2-20 > 2 0
Salbutamol concentration (pg/L)
Fig. 4. Relationship between salbutamol concentration range and 
twitch force (Pt). Values are means ± SE. Open bars, values from 
protocol B (strictly in vitro experiment); solid bars, values from 
protocol A  (subcutaneous salbutamol administration). Signifi­
















saline < 2 2-20 > 2 0
Salbutamol concentration (fJg/L)
Fig. 5. Relationship between salbutamol concentration range and 
maximal tetanic force (Pu). Values are means ± SE, Open bars, values 
from protocol B; solid bars, values from protocol A . Significantly 
different using Student’s f-test at: *P < 0.05; !|::i:P < 0.01.
activation in the rat diaphragm coincides with the 
maximal concentration reached in this muscle, which 
explains the time pattern found in Pt/P0.
The forces obtained in the saline bundles in protocol 
B  were slightly lower than those obtained in protocol A, 
although these differences were not statistically signifi­
cant (see Figs. 4 and 5). This may raise concerns about 
the stability of the diaphragm strips during the data 
collection. When we examined the data in protocols A  
and B  and expressed the force produced in the final 
160-Hz stimulation in the force-frequency protocol as a 
percentage of initial P0, the saline-treated rats reached 
levels of 100-103% of P0. In the salbutamol-treated 
animals, these percentages were slightly reduced, e.g., 
in the 100 jigA^ g group these values were 85-102% and 
in protocol B they were 91-103%. This indicates that at 
the end of all measurements the diaphragm strip force 
production was approximately equal to PQ values mea­
sured at the start, reensuring the stability of the 
diaphragm strips. Furthermore, the diaphragm strip 
dimensions in both protocols were within the critical 
radius for 0 2 diffusion into skeletal muscles at 37°C 
(—0.6 mm) (31). Therefore, we assume that hypoxia of 
the diaphragm strips did not influence force genera­
tion.
No significant differences in Pt and P0 between the 
two protocols were found at salbutamol concentrations 
of 2—20 pgA. However, at concentrations >20 pgA Pt 
and P0 were significantly higher in the in vivo experi­
ment {protocol A). Also, when we selected the data only 
on salbutamol zero concentrations in the salbutamol- 
treated animals, Pt and P0 were both significantly 
higher in the in vivo experiment. These data, however, 
include the serum samples of rats that had salbutamol 
concentrations below the limit of detection (0-2 pgA), 
which may have influenced the results. It could also 
indicate that the effect of salbutamol on rat diaphragm 
contractile properties is not solely a direct (32-adrener- 
gic effect on the muscle but is also be mediated by 
indirect effects. Subcutaneous administration of salbu-
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tamol may stimulate cardiac p2-adrenoceptors, which 
may increase heart rate (26). In addition, activation of 
p2-adrenoceptors in skeletal muscle resistance arteri­
oles may dilate diaphragm vessels (20). These effects 
may lead to an increased diaphragm blood flow, as was 
reported in rats after subcutaneous administration of 
the p2-adrenoceptor agonist clenbuterol (30). These 
alterations may explain the additional effects found in 
vivo but were not specifically explored in the present 
study.
Data on the diffusion rate of salbutamol into dia­
phragm muscle strips are not available to our knowl­
edge. In a pilot study, we found that an increase in Pt 
was present after a few minutes and that the maximum 
effect was reached within 10 min after addition of 
salbutamol. The maximal effect of the p2-adrenoceptor 
agonist terbutaline was also found within 10-15 min in 
a study investigating its in vitro effects on skeletal 
muscle contractile properties (5). Therefore, the thermo­
equilibration and diffusion period was set at 15 min in 
both protocols. In protocol A, there may have been some 
back diffusion from the diaphragm strip into the Krebs 
solution, since salbutamol is hydrophilic and rapidly 
dissociates from p2-adrenoceptors in rat lung prepara­
tions (27). We did not try to prevent this back diffusion 
by adding salbutamol to the Krebs solution because 
data on the concentration reached in the rat diaphragm 
after subcutaneous administration are not available. 
Besides, addition of salbutamol in protocol A  would 
interfere with our goal to study the mechanism of 
action.
Catecholamines exert opposing effects on fast- and 
slow-contracting skeletal muscles in vivo (1, 4). In cat 
soleus muscle, which contains predominantly type I 
(slow-contracting) muscle fibers, intravenously admin­
istered adrenaline depressed Pt? CT, RT1/2, and incom­
plete tetanic force but did not alter P0. However, in 
tibialis anterior muscle, a type II (fast-contracting) 
muscle, Pt, CT, RTi/2, and incomplete tetanic force were 
increased (4). In guinea pig soleus and extensor digi- 
torum longus muscles, similar effects were found with 
salbutamol and isoprenaline in vitro (1). A different 
response was observed in a study on the effects of 
terbutaline on skeletal muscles (5). This in vitro study 
reported an increase in Pt both in slow and in fast 
skeletal muscle fibers after addition of 10-5 M terbuta­
line. P0 was increased in slow but not in fast muscle 
fibers, and BT^ was decreased in both muscle types (5). 
Increased force production and CT were also found in 
the present study. RTi/2 was not altered in our study, 
but force generation at low stimulation frequencies was 
increased significantly This indicates that summation 
of force was enhanced. These effects could indicate an 
increased activation of type II muscle fibers in rat 
diaphragm. The diaphragm is a mixed skeletal muscle 
and contains -40% type I, 30% type Ha, and 30% type 
lib fibers (7). In studies investigating myosin heavy 
chain (MHC) distribution, the mature rat diaphragm 
consisted of -30% MHC-slow, -30% MHC-2A, -30% 
MHC-2X, and —10% MHC-2B fibers (15). In rat skel­
etal muscles, a strong correlation was found between 
p-adrenoceptor density and percentage of type I muscle
fibers (22) and for p-adrenoceptor density and succinic 
dehydrogenase activity (37). In contrast, 12,i5I-labeled 
cyanopindolol-binding affinity was significantly higher  ^
in type lib muscle fibers (22). In view of the results 
found in the present study, we speculate that p2-agonist 
treatment predominantly affects type II fibers in the 
rat diaphragm, and thus the diaphragm could be 
considered as a fast skeletal muscle in this respect
The design of the present study does not allow a 
direct comparison with previous animal studies (2,11,
12, 29). In these in vivo studies in anesthetized dogs, 
salbutamol increased twitch Pdi only during compen­
sated metabolic acidosis (12). In fatigued diaphragm, 
Pdi was not improved (11, 29). Salbutamol was applied 
intravenously in a bolus of 2.5-20 pg/kg (29) or as a 
15-min intravenous infusion in a relatively high dose of 
—0.6-2.2 pg * kg"1 * min“1 (recommended human dose is
0.04-0.3 pg’kg^'min"1 iv) (11, 12). However, terbuta­
line, in a dose of —25 ]ig/kg iv administered in 5 min, 
did increase Pdi in fatigued but not in fresh canine 
diaphragm both after direct and phrenic nerve stimula­
tion (2). This effect was blocked by the p-adrenoceptor 
antagonist propranolol (2). Likewise, fenoterol and 
broxaterol potentiated Pdi in fatigued but not in fresh 
canine diaphragm (8, 34). In fresh diaphragm, predomi­
nantly slow motor units are recruited for normal venti­
latory maneuvers (32). In this situation, the lack of 
effect of p-agonist treatment is in line with our specula­
tion that the p-agonist treatment predominantly af­
fects type II muscle fibers. Our results might also 
suggest improvement of diaphragm contractility in 
fatigued diaphragm after p2-adrenoceptor agonist treat­
ment, as indeed was found for terbutaline (2) and 
fenoterol (34). However, salbutamol increased Pdi only 
during compensated metabolic acidosis (12) and not in 
fatigued canine diaphragm (11, 29). Why salbutamol 
treatment failed in this respect remains unclear.
The effects of salbutamol on diaphragm function in 
healthy humans are contradicting. Javaheri et al. (14) 
found no effects of salbutamol on maximal Pdi in fresh 
or fatigued diaphragm after 3 days of oral treatment (4 
mg 3 times/day). Violante et al. (35) reported that 
intravenous administration of —0.05 pg* kg'1* min-1 
had no effect on Plmax and ventilatory endurance, but 
the duration of treatment was not mentioned (35). In 
contrast, Martineau et al. (23) reported a significant 
increase in Piraax after 14—21 days of oral treatment 
(8 mg 2 times/day). In studies investigating other (32- 
adrenoceptor agonist effects on nonfatigued diaphragm, 
similar effects are reported. In patients with chronic 
obstructive pulmonary disease (COPD), oral terbuta­
line administration (2.5 mg 3 times/day for 7 days) (33) 
as well as terbutaline inhalation (7 days 500-1,500 yig 
4 times/day) (13) did not improve Pdi (33) or Piinax (A  
33). In healthy adults, a single oral dose of 7.5 or 15 mg 
terbutaline (n = 4) or 4 mg tulobuterol (n = 5) also did 
not improve Pimax (17). Finally, studies with broxaterol 
in COPD patients reported an increase in Pimax after 
intravenous administration (200 pg in 10 min) (9) but 
no increase in Pinmx after 7 days of oral treatment
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(0.5 mg 3 times/day) (25), However, this last study did 
report an increased endurance time (25). In contrast to 
the animal studies, all human studies used maximal 
voluntary contractions. Furthermore, the human dia­
phragm has a slightly different fiber type composition, 
containing 55 ± 5% type I, 21 ± 6 % type Ila, and 24 ± 
3% type lib muscle fibers (19), but the total amount of 
oxidative fibers (type I and Ila) is approximately equal 
(~70% in rats and ~75% in humans) (7, 19), Further 
research is needed to determine the effects of salbuta­
mol on the human diaphragm in patients with COPD 
and in the complex situation of respiratory muscle 
failure.
In conclusion, in vitro force generation of rat dia­
phragm bundles can be improved by the (Vadrenergic 
agonist salbutamol. These effects are present after low 
subcutaneous doses and in clinically relevant concentra­
tions in vitro and appear to be concentration depen­
dent. Overall, the increases in force generation were 
slightly higher after subcutaneous administration, sug­
gesting that in vivo salbutamol may have additional 
positive inotropic actions on diaphragm contractility 
besides a direct (32-adrenergic effect on the muscle 
itself.
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